Savara Inc (NASDAQ:SVRA) Short Interest Declined By 8.6%

Savara Inc (NASDAQ:SVRA) had a decrease of its short interest by 8.6%. FINRA published in November SVRA’s total 1.50M short interest. That’s 8.6% down from 1.65M shares. Savara Inc (NASDAQ:SVRA) has 254,200 shares average volume. It’ll cost 6 days for SVRA to recover its former position. Savara Inc float short is 7.39%.

SVRA touched $10.88 during the last trading session after $0.11 change.Savara Inc. is uptrending after having risen 47.23% since November 10, 2017. SVRA has 353,341 volume or 117.99% up from normal. The stock outperformed the S&P 500 by 31.61%.

Savara Inc., a clinical-stage specialty pharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases.The company has $381.83 million market cap. The Company’s product pipeline comprises AeroVanc, a Phase III ready inhaled formulation of vancomycin for the treatment of persistent methicillin-resistant staphylococcus aureus and lung infection in cystic fibrosis patients; Molgradex, a Phase II/III stage inhaled granulocyte-macrophage colony-stimulating factor for the treatment of autoimmune pulmonary alveolar proteinosis; and Aironite, an inhaled nebulized sodium nitrite solution to treat heart failure with preserved ejection fraction.Last it reported negative earnings.

More recent Savara Inc. (NASDAQ:SVRA) news were released by Globenewswire.com, Seekingalpha.com and Streetinsider.com. The first one has “Savara to Host Third Quarter 2018 Financial Results and Business Update Conference Call on November 7, 2018” as a title and was released on November 01, 2018. The next is “Savara Inc. (SVRA) CEO Rob Neville on Q3 2018 Results – Earnings Call Transcript” on November 08, 2018. And last was released on October 31, 2018, called “Savara (SVRA) Reports Complete Enrollment in Molgradex OPTIMA Clinical Study for Treatment of NTM”.

Savara Inc. (NASDAQ:SVRA) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.